Abstract
The 2007 health care reform has introduced maximum prices for prescription drugs in German social health insurance. In contrast to internal reference pricing — which has been introduced in 1989 — maximum prices need to be based on an assessment performed by the IQWiG of the patient relevant costs and benefits of all therapeutic alternatives to the respective drugs. Alternatively, they can be negotiated between the peak organisation of social health insurers and individual manufacturers. Moreover, costs for research and development need to be taken into account. e aim to assess the feasibility of maximum prices in the context of German social health insurance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
